Miltenyi Biomedicine GmbH — Sponsor Intelligence | 9 EU Trials

Filter these 9 trials by condition, phase, country and more.

9 Registered trials

6 Recruiting

2 Completed trials

15 Countries active

16 Unique IMPs

100% Results reported

Phase II

Phase I/II

Phase I

Phase I (FiH)

Oversight events:

1 serious breach 10 unexpected events 1 corrective measure across 2 trials

100%

2 of 2 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

Top indications

9 total

DALY II USA/MB-CART2019.1 for DLBCL Pending

2023-508508-39-01 Phase II 2 countries ZAMTOCABTAGENE AUTOLEUCEL
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms Recruiting

2023-506348-17-00 Phase II 4 countries ZAMTOCABTAGENE AUTOLEUCEL
MB-CART2019.1 in refractory MS Recruiting

2024-517601-82-00 Phase I/II 1 country
MB-CART19.1 in refractory SLE Recruiting

2023-507654-33-00 Phase I/II 1 country
A study of the safety and efficacy of MB-dNPM-1-TCR.1 in patients with relapsed or refractory AML. Recruiting

2023-505806-41-00 Phase I (FiH) 1 country
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies Recruiting

2022-501648-14-00 Phase I/II 1 country AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIG…
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE Recruiting

2024-516819-24-00 Phase I/II 1 country AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIG…
DALY 2-EU Ended

2023-506270-13-00 Phase II 15 countries ZAMTOCABTAGENE AUTOLEUCEL
MB-CART19.1 r/r CD19+ BCM Ended

2024-513334-38-00 Phase I 1 country AUTOLOGOUS T-CELLS TRANSDUCED WITH LENTIVIRAL VECTOR EXPRESSING A CHIMERIC ANTIG…

Showing 1–9 of 9 trials